Residual HIV-1 persistence during suppressive HAART

Current Clinical Topics in Infectious Diseases

Volumn , Issue 21, 2001, Pages 1-30

  Pomerantz, Roger J ^a   Zhang, Hui ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; HIV INFECTIONS; HIV-1; HUMANS;

EID: 0035225147     PISSN: 01953842     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (213)

1. O'Brien W, Pomerantz RJ. AIDS and other diseases due to HIV infection. In: Nathanson N, ed. Viral pathogenesis. New York: Raven Press, 1997:813-857.
2. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373: 123-126.
3. Mellors J, Rinaldo C, Gupta P, et al. Prognosis in HIV infection predicted by the quantity of virus in plasma. Science 1996;272:1167-1170.
4. Piatak M, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993; 259:1749-1754.
5. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
6. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
7. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogs plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trial Group. 320 Study Team. N Engl J Med 1997;337:725-733.
8. Zhang H, Domadula G, Beumont M, et al. HIV-I in the semen of men receiving highly active anti-retroviral therapy. N Engl J Med 1998;339:1803-1809.
9. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:357-362.
10. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-358.
11. Piatak M, Saag M, Yang L, et al. High levels of HIV-1 in plasma during all stages of infection by competitive PCR. Science 1993;259:1749-1754.
12. Patterson B, Till M, Otto P, et al. Detection of HIV-1 DNA and RNA in individual cells by PCR-driven in situ hybridization and flow cytometry. Science 1993;260:976-979.
13. Peng H, Reinhart TA, Retzel EF, et al. Single cell transcript analysis of human immunodeficiency virus gene expression in the transition from latent to productive infection. Virology 1995;206:16-27.
14. Schnittman SM, Psallidopoulos MC, Lane HC, et al. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science 1989;245:305-308.
15. Koenig S, Gendelman HE, Orenstein JM, et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients. Science 1986;233: 1089-1093.
16. Zack JA, Arrigo SJ, Weitsman SR, et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990,61:213-222.
17. 1b phase of the cell cycle is required for completion of human immunodeficiency virus type I reverse transcription in T cells. J Virol 1998;72: 3161-3168.
18. Zhang H, Dornadula G, Pomerantz RJ. Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenvironments: an important stage for viral infection of nondividing cells. J Virol 1996; 70:2809-2824.
19. Zack JA, Haislip AM, Krogstad P, Chen IS. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life-cycle. J Virol 1992;66:1717-1725.
20. Bukrinsky MI, Stanwick TL, Dempsey MP, Stevenson M. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 1991;254:423-427.
21. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 1990;9:1551-1560.
22. Spina CA, Guatelli JC, Richman DD. Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J Virol 1995; 69:297-2988.
23. Roederer M, Raju PA, Mitra DK, Herzenberg LA. HIV does not replicate in naive CD4 T cells stimulated with CD3/CD28. J Clin Invest 1997; 99:1555-1564.
24. Tang S, Patterson B, Levy JA. Highly purified quiescent human peripheral blood CD4+ T cells are infectible by human immunodeficiency virus but do not release virus after activation. J Virol 1995;69:5659-5665.
25. Woods TC, Roberts BD, Butera ST, Folks TM. Loss of inducible virus in CD45RA naive cells, after human immunodeficiency virus-I entry accounts for preferential viral replication in CD45RO memory cells. Blood 1997;89:1635-1641.
26. Chun TW, Chadwick K, Margolick J, Siliciano RF. Differential susceptibility of naive and memory CD4+ T cells to the cytopathic effects of infection with human immunodeficiency virus type I strain LAI. J Virol 1997;71:4436-4444.
27. Chou CS, Ramilo O, Vitetta ES. Highly purified CD25-resting T cells cannot be infected de novo, with HIV-1. Proc Natl Acad Sci USA 1997;94:1361-1365.
28. +) T cells are infected in human immunodeficiency virus type I-infected individuals. J Virol 1999;73:6430-6435.
29. Kinoshita S, Chen BK, Kaneshima H, Nolan GP. Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell 1998;95:595-604.
30. Pomerantz RJ, Trono D, Feinberg MB, Baltimore D. Cells non-productively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency. Cell 1990;61:1271-1276.
31. Butera ST, Robers BD, Lam L, et al. Human immunodeficiency virus type 1 RNA expression by four chronically infected cell lines indicates multiple mechanisms of latency. J Virol 1994;68: 2726-2730.
32. Michael NL, Morrow P, Mosca J, et al. Induction of human immunodeficiency virus type 1 expression in chronically infected cells is associated primarily with a shift in RNA splicing patterns. J Virol 1991;65:1291-1303.
33. Seshamma T, Bagasra O, Trono D, et al. Blocked early-stage latency in the peripheral blood cells of certain individuals infected with human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1992;89:10663-10667.
34. Comar M, Simonelli C, Zanussi S, et al. Dynamics of HIV-1 mRNA expression in patients with long-term nonprogressive HIV11 infection. J Clin Invest 1997;100:893-903.
35. Michael NL, Mo T, Merzouki A, et al. Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort. J Virol 1995;69:1868-1877.
36. Sanchez G, Xu X, Chermann JC, Hirsch I. Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals. J Virol 1997;71:12233-12240.
37. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;3:117-122.
38. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997;387: 188.
39. Chun TWL, Carruth D, Finzi D, et ai. Quantification of latent tissue reservoirs and total body viral load in HIV-I infection. Nature 1997;387: 183-188.
40. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-1295.
41. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active anti-retroviral therapy. Science 1997;278:1295-1300.
42. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active anti-retroviral therapy. Proc Natl Acad Sci USA 1997;94:13193-13197.
43. Chun TW, Engle D, Berrey MM, et al. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998;95:8869-8873.
44. Chun TW, Engel D, Mizeh SB, et al. Induction of HIV-1 replication in latently infected CD4+ T-cells using a combination of cytokines. J Exp Med 1998;188:83-91.
45. Moriuchi H, Moriuchi M, Mizell SB, et al. In vitro reactivation of human immunodeficiency virus 1 from latently infected, resting CD4+ T-cells after bacterial stimulation. J Infect Dis 2000;181:2041-2044.
46. Persaud D, Pierson T, Ruff C, et al. A stable latent reservoir for HIV-1 in resting CD4+ T-lymphocytes in infected children. J Clin Invest 2000;105:995-1003.
47. Poggi C, Profizi N, Djediouane A, et al. Long-term evaluation of triple nucleoside therapy administered from primary HIV-1 infection. AIDS 1999;13:1213-1220.
48. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997;276:960-964.
49. Kazanjian P, Adams D, Kaul D, et al. HIV replication in macrophages isolated from HIV-infected patients receiving protease inhibitors. Abstract #362. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
50. Lambotte O, Taoufik Y, deGoer MG, et al. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J Acq Immune Defic Syndr 2000;23:114-119.
51. Pierson T, Hoffman TL, Blanlson J, et al. Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J Virol 2000;17:7824-7833.
52. Bunce C, Bell EB. CD45RC isoforms define two types of CD4 memory T cells, one of which depends on persisting antigen. J Exp Med 1997; 185:767-776.
53. Dyrhol-Riise AM, Voltersvik P, Olofsson J, Asjo B. Activation of CDS T cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection. AIDS 1999;13:2365-2376.
54. Orenstein JM, Feinberg M, Yoder C, et al. Lymph node architecture preceding and following 6 months of potent antiviral therapy: follictilar hyperplasia persists in parallel with p24 antigen restoration after involution and CD4 cell depletion in an AIDS patient. AIDS 1999;13: 2219-2229.
55. Veazey RS, DeMaria MA, Chalifoux LV, et al. Gastrointestinal tract as a major site of CD4+ T-cell depletion and viral replication in SIV infection. Science 1998;280:427-431.
56. Kotler DP, Shimada T, Snow G, et al. Effect of combination antiretroviral therapy upon rectal mucosal HIV RNA burden and mononuclear cell apoptosis. AIDS 1998;12:597-604.
57. Poles M, Elliott J, Brow S, et al. HIV-1 is detectable in mucosal biopsies in patients with undetectable plasma viral loads. Abstract #160. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, Jan 30, 1999.
58. Lampinen TM, Critchlow CW, Kuypers JM, et al. Association of antiretroviral therapy with detection of HIV-1 RNA and DNA in the anorectal mucosa of homosexual men. AIDS 2000;14: F69-F75.
59. Gunthard HF, Wong JK, Ignacio CC, et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent anti-retroviral therapy. J Virol 1998;72:2422-2428.
60. Fouchier RAM, Groeninl M, Kootstra NA, et al. Phenotype associated sequence variation in the third variable region of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992;66:3183-3187.
61. Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 1993;261: 1179-1181.
62. Zhang LQ, MacKenzie P, Cleland A, et al. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol 1993;67:3345-3356.
63. Zhu T, Wang N, Carr A, et al. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol 1996;79: 3098-3107.
64. van't Wout A, Kootstra NA, Mulder-Kampinga GA. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral and vertical transmission. J Clin Invest 1994;94:2060-2067.
65. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med 1996; 2:1240-1243.
66. Paxton WA, Lui R, Kang S, et al. Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines. Virology 1998;244:66-73.
67. Veenstra J, Schuurman R, Cornelissen M, et al. Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. Clin Infect Dis 1995;21:556-560.
68. Ippolito G, Del Poggio P, Ariei C, et al. Transmission of zidovudine-resistant HIV during a bloody fight. JAMA 1994;272:433-434.
69. Angarano G, Monno L, Appice A, et al. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts. AIDS 1994;8:1013-1014.
70. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999;282:1135-1141.
71. Little SJ, Daar ES, D' Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV-infection. JAMA 1999;282: 1142-1149.
72. Salomon H, Wainberg MA, Brenner B, et al. Prevalence of HIV-1 resistance to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. AIDS 2000;14: F18-F23.
73. Pomerantz RJ. Primary HIV-1 tesistance: a new phase in the epidemic? JAMA 1999;282:1177-1179.
74. Liuzzi G, Chirianni A, Clementi M, et al. Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study. AIDS 1996;10:F51-F56.
75. Pomerantz RJ, Kuritzkes DR, de la Monte SM, Hirsch MS. Infection of the retina by human immunodeficiency virus type 1. N Engl J Med 1987;317:1643-1647.
76. Ho DD, Pomerantz RJ, Kaplan JC. Pathogenesis of infection with human immunodeficiency virus. N Engl J Med 1987;317:278-286.
77. Bruggeman LA, Ross MD, Tanji N, et al. The kidney is a previously unrecognized reservoir for HIV-1 replication. Abstract #161. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
78. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000;14:237-242.
79. Clayette P, Jorajuria S, Dormont D. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors [editorial]. AIDS 2000;14:235-236.
80. Aweeka F, Jayewardene A, Staprans S, et al. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex. J Acq Immune Defic Syndr 1999;20:39-43.
81. Tashima KT, Caliendo AM, Ahmad M, et al. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and Efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis 1999;180:862-864.
82. Martin C, Sonnerborg A, Svensson JO, Stahle L. Indinavir-based treatment of HIV-1-infected patients: efficacy in the central nervous system. AIDS 1999;13:1227-1232.
83. Gisolf EH, Enting RH, Jurriaans S, et al. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine. AIDS 2000;14:1583-1589.
84. Kravcik S, Gallicano K, Roth V, et al. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir. J Acq Immune Defic Syndr 1999;21:371-375.
85. Eggers CC, Lunzen J, Buhk T, Stellbrink HJ. HIV infection of the central nervous system is characterized by rapid turnover of viral RNA in cerebrospinal fluid. J Acq Immune Defic Syndr 1999;20:259-264.
86. van Praag RME, Weverling GJ, Portegics P, et al. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 2000;14:1187-1194.
87. Taylor S, Back DJ, Workman J, et al. Poor penetration of the male genital tract by HIV-1 protease inhibitors. AIDS 1999;13:859-872.
88. Eron JJ Jr, Smeaton LM, Fiscus SA, et al. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen. J Infect Dis 2000;181:1622-1628.
89. Domadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in the blood plasma of patients on suppressive highly active antiretroviral therapy (HAART). JAMA 1999;282: 1627-1632.
90. Pereira AS, Kashuba ADM, Fiscus SA, et al. Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden. J Infect Dis 1999;180:2039-2043.
91. Vernazza PL, Gilliam BL, Dyer J, et al. Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS 1997;11:987-993.
92. Vernazza PL, Troiani L, Flepp MJ, et al. Potent antiretroviral treatment of HIV infection results in suppression of the seminal shedding of HIV. AIDS 1999;14:117-121.
93. Vernazza PL, Gilliam BL, Flepp M, et al. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS 1997;11:1249-1254.
94. Barroso PF, Schechter M, Gupta P, et al. Effect of antiretroviral therapy on HIV shedding in semen. Ann lut Med 2000;133:280-284.
95. Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000;14: 415-421.
96. Mayor KH, Boswell S, Goldstein R, et al. Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy. Clin Infect Dis 1999;28: 1252-1259.
97. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000;342:921-929.
98. Gupta P, Leroux C, Patterson B, et al. HIV-1 shedding pattern in semen correlates with the compartmentalization of viral quasispecies between blood and semen. Abstract #114. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
99. Schacker T, Pryor J, Nguyen P, et al. Sites of productive infection of HIV in the male GU tract. Abstract #115. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
100. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999;340:1605-1613.
101. Gunthard HF, Frost SDW, Leigh-Brown AJ, et al. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol 1999;73:9404-9412.
102. Martinez MA, Cababa M, Ibanez A, et al. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged depression of plasma viremia. Virology 1999;256:180-187.
103. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999;340:1614-1622.
104. Imamichi M, Crandall K, Jiang MK, et al. Infectious HIV-1 derived from PBMC co-culture reflects a subset of transcriptionally active variants present in PBMC in patients with prolonged suppression of plasma viremia with HAART. Abstract #TuPeA3101. XIII International Conference on AIDS, Durban, South Africa, July 9-14, 2000.
105. Bucy RP, Kilby JM, Goepfert PA, et al. Persistent vRNA in PBMC from HIV-infected patients on potent antiretroviral therapy is associated with rare vRNA + cells. Abstract #140. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
106. Yerly S, Pemeger TV, Vora S, et al. Decay rates of cell-associated HIV-1 DNA correlate with residual viral replication in patients treated during primary HIV-1 infection. Abstract #210. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
107. Gunthard HF, Wong JK, Spina CA, et al. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis 2000;181: 522-531.
108. Zhang Z-Q, Schuler T, Zupaneic M, et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 1999;286:1353-1357.
109. Derdeyn CA, Kilby JM, Diego Miralles G, et al. Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1 infected subjects in the absence or presence of effective therapy. J Infect Dis 1999; 180:1851-1862.
110. Zhu T, Muthui D, Holte S, et al. HIV-1 latent reservoirs renewed by viral replication in activated CD4+ T-lymphocytes, monocytes, and resting CD4+ T-lymphocytes in patients receiving potent therapy. Abstract #136. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
111. Unutmaz D, KewalRamani VN, Marmon S, Littman DR. Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J Exp Med 1999;189:1735-1746.
112. Zhang H, Zhang Y, Spicer TP, et al. Reverse transcription takes place within extracellular HIV-1 virions: potential biological significance. AIDS Res Hum Retrovirus 1993;9:1287-1296.
113. Zhang H, Domadula G, Wu Y, et al. Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo. J Virol 1996;70:628-634.
114. Natarajan V, Bosche M, Metcalf JA, et al. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Lancet 1999;353: 119.
115. LaFeuillade A, Chollet L, Hittinger G, et al. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/mL. J Infect Dis 1998;177:235-238.
116. Sharkey ME, Teo I, Greenough T, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy. Nature Med 1999,6:76-81.
117. Raboud JM, Montaner JSG, Conway B, et al. Suppression of plasma viral load below 20 copies/mL is required to achieve a long term response to therapy. AIDS 1998;12:1619-1624.
118. Pilcher CD, Miller WC, Beatty ZA, Eron JJ. Detectable HIV-1 RNA at levels below quantifiable limits by Amplicor HIV-1 monitor is associated with virologic relapse on antiretroviral therapy. AIDS 1999;13:1337-1342.
119. Raboud JM, Rae S, Hogg R, et al. Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation J Infect Dis 1999;180:1347-50.
120. Garcia F, Vidai C, Plna M, et al. Residual low-level viral replication could explain discrepancies between viral load and CD4+ cell response in human immunodeficiency virus-infected patients receiving antiretroviral therapy. Clin Infect Dis 2000;30:392-394.
121. Luzuriaga K, McManus M, Catalin M, et al. Early therapy of vertical HIV-1 infection: evidence for cessation of viral replication and absence of virus-specific immunity. Abstract #211. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
122. Harrigan PR, Whaley M, Montaner JSG. Rate of HIV-1 RNA rebound upon stopping antiretro-viral therapy. AIDS 1999;13:F59-F62.
123. Montaner JSG, Harris M, Mo T, Harrigan RP. Rebound of plasma HIV viral load following prolonged suppression with combination therapy. AIDS 1998;12:1398-1399.
124. Orenstein JM, Bhat N, Yoder C, et al. Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression. AIDS 2000;14:1709-1715.
125. Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999;340: 1683.
126. Patterson BK, McCalister S, Schutz M, et al. Persistence of intercellular HIV-1 mRNA (in-cell viral load) correlates with HIV-specific immune responses in HIV-infected subjects on stable HMRT therapy. Abstract #784. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
127. Garcia F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999;13:F79-F86.
128. Neumann AU, Tubiana R, Calvez V, et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. AIDS 1999;13:677-683.
129. Hockett RD, Kilby JM, Dcrdeyn CA, et al. Constant mean viral copy number per infected cell in tissues regardless of high, low or undetectable plasma HIV RNA. J Exp Med 1999;189:1545-1554.
130. Finzi D, Blankson J, Siliciano JS, et al. Latent infection of CD4+ T-cells provides a mechanism for lifelong persistence of HIV-1 even in patients on effective combination therapy. Nature Med 1999;5:512-517.
131. Fischer M, Gunthard HF, Opravil M, et al. Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy. AIDS Res Hum Retrovirus 2000;16:1135-1140.
132. Enting RH, Hoetelmans RMW, Lange JMA, et al. Antiretroviral drugs and the central nervous system. AIDS 1998;12:1941-1955.
133. Chun T-W, Davey R, Ostrowksi M, et al. Relationship between pre-existing latent viral reservoirs and the re-emergence of plasma viremia following discontinuation of highly active antiretroviral therapy. Abstract #23. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
134. Hlavacek WS, Wofsy C, Perelson AS. Dissociation of HIV-1 from follicular dendritic cells during HAART: mathematical analysis. Proc Natl Acad Sci USA 1999;96:14681-14686.
135. Geijtenbeek TB, Kwon DS, Torensma R, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000;100:587-597.
136. Kacani L, Prodinger WM, Sprinzl GM, et al. Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2. J Virol 2000;74: 7997-8002.
137. Moir S, Malaspina A, Li Y, et al. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J Exper Med 2000; 192:637-646.
138. Grossman Z, Polis M, Feinberg MB, et al. Ongoing HIV dissemination during HAART. Nature Med 1999;5:1099-1104.
139. Ferguson NM, deWolf F, Ghani AC, et al. Antigen-driven CD4+ T-cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy. Proc Natl Acad Sci USA 1999;96:15167-15172.
140. Chun T-W, Engel D, Mizell SB, et al. Effect of interletitin-2 on the pool of latently infected resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nature Med 1999;5:651-655.
141. Lewin SR, Vesanen M, Kostrikis L, et al. Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J Virol 1999;73: 6099-7103.
142. Marodon G, Warren D, Filomio MC, Posnett DN. Productive infection of double-negative T cells with HIV in vivo. Proc Natl Acad Sci USA 1999;96:11958-11963.
143. 6/μL CD4 cells treated with highly active antiretroviral therapy. AIDS 2000;14:23-29.
144. Ramratnam B, Mittler JE, Zhang L, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nature Med 1999; 6:82-85.
145. Havlir D, Hirsch MS, Richman DD, et al. Prevalence and predictive value of intermittent viremia in patients with viral suppression. Abstract #TuPeB3195. XIII International Conference on AIDS, Durban, South Africa, July 9-14, 2000.
146. Easterbrook P, Ives N, Peters B, Gazzard B. The natural history and clinical significance of intermittent virological "blips" in patients who attain an initially undetectable viral load (VL) on HAART. Abstract #WeOrB610. XIII International Conference on AIDS, Durban, South Africa, July 9-14, 2000.
147. Ward D, Sklar P. The significance of low-level viremia in patients with previously "undetectable" HIV-1 RNA levels. Abstract #MoPpB1019. XIII International Conference on AIDS, Durban, South Africa, July 9-14, 2000.
148. Blankson J, Finzi D, Pierson T, et al. Biphasic decay of latent HIV-1 in resting CD4+ T cells in acute seroconverters. Abstract #137. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
149. Martinez-Picado J, DePasquale MP, Kartsonis NA, et al. Selection of antiretroviral resistance in the latent reservoir of human immunodeficiency virus type 1 during successful therapy. Abstract #238. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
150. Fraser C, Ferguson NM, Ghani AC, et al. Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs. AIDS 2000;14:659-669.
151. Prins JM, Jurrianns S, van Praag RME, et al. Immuno-activation with anti-CD3 and recombinant human IL-2 and HIV-1-infected patients on potent antiretroviral therapy. AIDS 1999;13: 2405-2410.
152. Chun T-W, Davey RT Jr, Engel D, et al. Reemergence of HIV after stopping therapy. Nature 1999;401:874-875.
153. Stellbrink HJ, Van Lunzen J, Westby M, et al. Influence of interleukin-2 (IL-2) on productive and latent HIV-1 infection and on viral rebound. Abstract #240. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
154. Davey RT Jr, Bhat N, Yoder C, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999;96:15109-15114.
155. Lafeuillade A, Poggi C, Chollet L, et al. Aggressive HAART + IL-2 is unable to induce HIV remission in early-stage disease after 18 months. Abstract #544. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
156. Chun T-W, Davey RT Jr, Ostrowsi M, et al. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nature Med 2000;6:757-761.
157. Taoufik Y, Lambotte O, Wallon C, et al. In vitro, recombinant interleukin-2 and HIV-specific antigens activate HIV latently infected lymphocytes from patients on prolonged HAART. Abstract #378. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
158. Campbell TB, Sevin A, Coombs RW, et al. Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Blood 2000;95: 48-55.
159. Gunthard HF, Wong JK, Spins CA, et al. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis 2000;181: 522-531.
160. Wong J, Billingsley J, Wang Z, et al. Induction and elimination of latent HIV via T-cell activation. Abstract #547. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
161. Giacca M, Zanussi S, Comar M, et al. Treatment of human immunodeficiency virus infection with hydroxyurea: virologic and clinical evaluation. J Infect Dis 1996;174:204-209.
162. Rutschmann OT, Opravil M, Itecnb A, et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. AIDS 1998;12:F71-F77.
163. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus type 1 replication. Science 1994;266:801-804.
164. Gao W-Y, Cara A, Gallo RC, Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1993;90:8925-8928.
165. Meyerhans A, Vartanian J-P, Hultgren C, et al. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleotide triphosphate pools. J Virol 1994;68:535-540.
166. DeBoer RJ, Boucher CAB, Pcrelson AS. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine. AIDS 1998;12:1567-1570.
167. Vila J, Nugier F, Bargues G, et al. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide [letter]. Lancet 1997;2:88-89.
168. Zala C, Salomon H, Gun A, et al. Viral load rebound upon discontinuation of d4T + ddI and NVP with or without hydroxyurea (HU) during primary HIV infection (PHI). Abstract #558. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
169. Collin M, Gordon S. The kinetics of human immunodeficiency virus reverse transcription are slower in primary human macrophages than in a lymphoid cell line. Virology 1993;200:114-120.
170. O'Brien WA, Namazi A, Kalhor H, et al. Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors. J Virol 1994;68:1258-1263.
171. Lori F, Jessen H, Lieberman J, et al. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J Infect Dis 1999;180:1827-1832.
172. Hoen B, Dumon B, Harzic M, et al. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 Trial. J Infect Dis 1999;180:1342-1346.
173. Margolis D, Heredia A, Gaywee J, et al. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acq Immune Defic Syndr 1999;21:362-370.
174. Chapuis AG, Rizzzardi GP, D'Agostino C, et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nature Med 2000;6:762-768.
175. Aleman S, Visco-Comandini U, Lore K, Sonnerborg A. Long-term effects of antiretroviral combination therapy on HIV type I DNA levels. AIDS Res Hum Retrovirus 1999;15:1249-1254.
176. Zaunders JJ, Cunningham PH, Kelleher AD, et al. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. J Infect Dis 1999;180:320-329.
177. Ibanez A, Puig T, Elias J, et al. Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999;13:1045-1049.
178. Brodier SJ, Berrey MM, Patterson BK, et al. Comparison of cell-associated HIV-1 DNA and RNA in triple-drug-treated versus untreated persons with primary HIV-1: evidence for persistent viral reservoirs. Abstract A 561. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
179. Yerly S, Kaiser L, Perneger TV, et al. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. AIDS 2000;14:243-249.
180. Smith C, Lilly S, Miralles GD. Treatment of HIV infection with cytoreductive agents. AIDS Res Hum Retrovirus 1998;14:1305-1313.
181. Berger EA, Moss B, Pastan I. Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART. Proc Natl Acad Sci USA 1998;95:11511-11513.
182. McCoig C, Van Dyke G, Chou C-S, et al. An anti-CD45RO immunotoxin eliminates T-cells latently infected with HIV-1 in vitro. Proc Natl Acad Sci USA 1999;96:11482-11485.
183. Goldstein H, Pettocllo-Mantovani M, Bera TK, et al. Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo acivity of combination antiretroviral therapy in thy/liv-SCID-hu mice. J Infect Dis 2000;181:921-926.
184. Gabarre J, Azar N, Autran B, et al. High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. Lancet 2000;355:1071-1072.
185. Ortiz GM, Nixon DF, Trkola A, et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest 1999;104:R13-R18.
186. Kalams SA, Goulder PJ, Shea AK, et al. Levels of human immunodeficiency virus type 1 specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J Virol 1999;73:6721-6728.
187. Binley JM, Schiller DS, Ortiz GM, et al. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. J Infect Dis 2000;181:1249-1263.
188. Haslett PAJ, Nixon DF, Shen Z, et al. Strong human immunodeficiency virus (HIV)-specific CD4+ T-cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. J Infect Dis 2000;181:1264-1272.
189. Rosenberg ES, Billingsley JM, Calieno AM, et al. Vigorous HIV-1-specific CD4+ T-cell responses associated with control of viremia. Science 1997;278:11447-11450.
190. Clerici M, Seminari E, Suter F, et al. Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naive patients with undetectable viraemia. AIDS 2000;14:109-116.
191. Decks SG, Wrin T, Hoh R, et al. Virologic and immunologic evaluation of structured treatment interruptions (STI) in patients experiencing long-term virologic failure. Abstract #LB10. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
192. Garcia F, Plana M, Ortiz GM, et al. Structured cyclic antiretroviral therapy interruption (STI) in chronic infection may induce immune responses against HIV-1 antigen associated with spontaneous drop in viral load. Abstract #LB11. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
193. Kilby JM, Saag MS, Goeppert PA, et al. Significant delay in plasma vRNA rebound during a scheduled treatment interruption in HIV-1 chronically infected patients previously on effective therapy. Abstract #359. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
194. Ionnidis JPA, Havlir DV, Tebas P, et al. Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication. Abstract #360. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
195. Ruiz L, Martinez-Picado J, Romeu J, et al. Structured treatment interruption in chronically HIV-1-infected patients after long-term viral suppression. AIDS 2000;14:397-403.
196. Altfeld M, Rosenberger ES, Eldridge RL, et al. Increase in breadth and frequency of CTL responses following structured therapy interruptions in individuals treated with HAART during acute HIV-1 infection. Abstract #357. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
197. Carcelain G, Tubiana R, Mollet L, et al. Intermittent interruptions of antiretroviral therapy in chronically HIV-1 infected patients do not induce immune control of HIV. Abstract #356. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
198. Orenstein JM, Bhat N, Yoder C, et al. Rapid activation of lymph nodes upon interrupting HAART in HIV-infected patients following prolonged viral suppression. Abstract #358. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb. 2 2000.
199. Lori F, Foli A, Maserati R, et al. Control of viremia after treatment interruption. Abstract #352. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
200. Hatano H, Vogel S, Metcalf J, et al. Plasma viral loads approximate pre-HAART levels after discontinuation of HAART. Abstract #3-49. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
201. Harrigan PR, Whaley M, Dong W, et al. No detectable HIV RNA in thirteen individuals months after stopping antiretroviral therapy. Abstract #351. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Jan 30-Feb 2, 2000.
202. Tremblay C, Rosenberg E, Giguel F, et al. Stable peripheral blood HIV-1 reservoirs following structured therapy interruptions (STI) in two subjects. Abstract #WePeB4287. XIII International Conference on AIDS, Durban, South Africa, July 9-14, 2000.
203. Dybul M, Yoder D, Belson M, et al. Short cycle intermittent HAART: a pilot study. Abstract #LbOr12. XIII International Conference on AIDS, Durban, South Africa, July 9-14, 2000.
204. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-526.
205. Hel Z, Venzon D, Poudyal M, et al. Viremia control following antiretroviral treatment and therapeutic ' immunization during primary SIV251 infection of macaques. Nature Med 2000;6:1140-1146.
206. Markowitz M, Vesanen M, Tenner-Racz K, et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 1999;179:525-537.
207. Michie CA, McLean A, Alcock C, Beverley PCL. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 1992;360: 264-265.
208. Mclean AR, Michie CA. In vivo estimates of division and death rates of human T lymphocytes. Proc Natl Acad Sci USA 1995;92: 3707-3711.
209. Hellerstein M, Hanley MB, Cesar D, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nature Med 1999;5:83-89.
210. McCune JM, Hanley MB, Cesar D, et al. Factors influencing T-cell turnover in HIV-1-seropositive patients. J Clin Invest 2000;105: R1-R8.
211. Hege K, Wagnert B, Mitsuyasu R, et al. HIV-1 specific T-cell gene therapy suppresses viral load rebound in subjects on highly active antiretroviral therapy (HAART). American Society of Gene Therapy Meeting, Denver, CO, May 30, 2000.
212. Mukhtar M, Duke H, BouHamdan M, Pomerantz RJ. Anti-human immunodeficiency virus type 1 gene therapy in human central nervous system-based cells: an initial approach against a potential viral reservoir. Human Gene Ther 2000;11:347-359.
213. Pomerantz RJ. Residual HIV-1 disease in the era of highly active antiretroviral therapy. N Engl J Med 1999;340:1672-1674.